Biopharma Report

A high bar for exits hits biopharma startups  

Biopharma remains a strong sector in venture capital, showing resilience through ongoing funding rounds. However, overall exit value has sharply declined QoQ, dropping from $10.0 billion in Q1 2024 to less than half that amount in Q2, reaching $4.5 billion, according to our latest Emerging Tech Research. 

Only biopharma companies with robust clinical data are succeeding in IPOs, leaving the majority of startups facing significant barriers to exit. This trend suggests that many startups, particularly those innovating in areas like gene editing, targeted cancer treatment, and AI drug discovery platforms, may need to continue their development independently rather than seeking acquisition by Big Pharma.